Prescient Design
Prescient Design is an AI-native biotechnology company building proprietary machine learning models for macromolecular design and drug discovery. Founded by NYU and Flatiron Institute researchers, it operates as an embedded ML unit inside Genentech's Research and Early Development organization.
- Company typePrivate
- Founded2021
- HeadquartersSouth San Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Prescient Design does
Prescient Design is a biotechnology company that applies machine learning and artificial intelligence to macromolecular and drug discovery. Founded in 2021 by computer science and computational biology faculty from New York University and the Flatiron Institute — Vladimir Gligorijevic, Richard Bonneau, and Kyunghyun Cho — the company builds a proprietary ML platform aimed at accelerating and expanding the scope of pharmaceutical R&D, including tasks such as synthesis planning and molecular optimization. The underlying technology is described as a novel method architecture for ML-driven drug discovery, and the team operates as a unified ML/AI platform rather than a portfolio of discrete products.
Prescient Design's business model is non-commercial: rather than selling software or services to external customers, the company joined Genentech's Research and Early Development (gRED) organization and now operates as an internal, embedded ML unit supporting Genentech's drug discovery pipeline. Genentech, in turn, is a wholly-owned subsidiary of Roche Holding AG, so Prescient Design's effective go-to-market is internal Roche/Genentech R&D consumption. Pricing, customer logos, and revenue are not publicly disclosed because there is no external sales motion; the unit's distribution channel is effectively OEM/embedded inside Genentech's research workflow, headquartered in South San Francisco with 1–10 employees and active hiring for Machine Learning Scientists focused on synthesis planning and optimization.
Prescient Design firmographics
Firmographics- Name
- Prescient Design
- Legal name
- Prescient Design
- Website
- https://prescient.design
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Prescient Design is an AI-native biotechnology company building proprietary machine learning models for macromolecular design and drug discovery. Founded by NYU and Flatiron Institute researchers, it operates as an embedded ML unit inside Genentech's Research and Early Development organization.
- Ownership category
- akta.pro rank
Prescient Design industry classification
Industry- Product category
- AI-Driven Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where Prescient Design is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Prescient Design business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations
Distribution channels1 record
Marketing channels2 records
Prescient Design product offering
Product offeringCore offering
Prescient Design builds and operates a machine learning and artificial intelligence platform for drug discovery, with focus on macromolecular design and generative biology. The platform is integrated into Genentech's Research and Early Development (gRED) organization to accelerate the development of new medicines by combining advanced ML/AI approaches with Genentech's computational capabilities. The team applies synthesis planning, protein modeling, and AI-driven optimization to develop potential medicines for previously untreatable diseases.
Product overview
Prescient Design is a single, unified machine learning platform for drug discovery. Founded by computer science and computational biology faculty from NYU and the Flatiron Institute, the platform applies cutting-edge machine learning and AI technology to accelerate drug discovery efforts within Genentech's Research and Early Development (gRED) organization. The team combines advanced ML/AI approaches with Genentech's growing internal computational capabilities to develop potential medicines that treat diseases previously untackleable.
Differentiator
Problem solved
Functional benefit
Products and services
- Prescient Design Platform A machine learning and artificial intelligence platform focused on drug discovery and macromolecular design, integrated into Genentech's Research and Early Development (gRED) organization to accelerate the development of new medicines for patients.
Companies that use Prescient Design
Customer profileSegments1 record
Ideal customer profiles1 record
Prescient Design technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature1 record
Prescient Design partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- New York UniversitycorePrescient Design was co-founded by computer science and computational biology faculty members from New York University. The NYU connection provides ongoing academic collaboration and access to leading ML research talent.
- Flatiron InstitutecorePrescient Design was co-founded by faculty members from the Flatiron Institute, which contributed computational biology expertise and research capabilities to the company's founding.
- GenentechcorePrescient Design has joined Genentech's Research and Early Development organization (gRED) to apply machine learning technology to drug discovery. The company's platform and expertise are integrated with Genentech's growing internal computational capabilities.
Recent moves5 records
Expansion highlights4 records
Prescient Design competitors and assessment
Company assessmentDirect peers
- Exscientia: Uses AI-driven drug design (including generative chemistry) to accelerate small-molecule discovery, with pharma partnerships analogous to Prescient Design's pharma-embedded model.
- Atomwise: Applies deep learning and structure-based design to small-molecule drug discovery; comparable as an AI platform company working on macromolecular and target-based design.
- Recursion Pharmaceuticals: Combines high-throughput experimental biology with machine learning to discover and develop therapeutics at scale; comparable in applying AI/ML across the drug discovery workflow.
- Schrödinger, Inc. Provides computational chemistry and machine learning software for drug discovery and materials science; directly comparable as an AI/ML platform company serving pharma R&D.
- Insilico Medicine: AI-driven drug discovery company applying generative AI and deep learning to identify novel targets and design new molecules, directly comparable to Prescient Design's ML-for-drug-discovery mandate.
- Isomorphic Labs: Alphabet/DeepMind-founded AI drug discovery company building computational models to predict drug behavior; closely aligned with Prescient Design's AI-for-medicinal-design focus.
Broad incumbents
- BenevolentAI: Applies AI to biomedical knowledge graphs and drug discovery across multiple therapeutic areas; a broader incumbent in the AI-for-drug-discovery space with overlapping platform ambitions.
Emerging players
- Genesis Therapeutics: Emerging AI drug discovery company combining graph neural networks and protein dynamics simulation; comparable as a younger AI-for-drug-discovery peer with overlapping generative modeling ambitions.
- Iambic Therapeutics: AI-driven drug discovery company using neural networks for molecular property prediction and design; comparable as a focused AI platform in small-molecule discovery.
- XtalPi: AI- and physics-based drug discovery platform serving global pharma partners, with comparable AI-driven molecular design and crystal-structure prediction capabilities.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Prescient Design social profiles
Digital presencePrescient Design financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prescient Design leadership team
Management profileNumber of profiles
Profiles3 records
Prescient Design funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prescient Design M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prescient Design
What does Prescient Design do?
Prescient Design builds and operates a machine learning and artificial intelligence platform for drug discovery, with focus on macromolecular design and generative biology. The platform is integrated into Genentech's Research and Early Development (gRED) organization to accelerate the development of new medicines by combining advanced ML/AI approaches with Genentech's computational capabilities. The team applies synthesis planning, protein modeling, and AI-driven optimization to develop potential medicines for previously untreatable diseases.
Is Prescient Design a public or private company?
Prescient Design is a private company. It is classified as corporate owned and is currently operating.
When was Prescient Design founded?
Prescient Design was founded in 2021. It employs 1 to 10 people.
Where is Prescient Design based?
Prescient Design is headquartered in South San Francisco, United States, in the North America region.
Who are Prescient Design's main competitors?
Direct peers on record are Exscientia, Atomwise, Recursion Pharmaceuticals, Schrödinger, Inc., Insilico Medicine and Isomorphic Labs. BenevolentAI is listed as a broad incumbent. Emerging players are Genesis Therapeutics, Iambic Therapeutics and XtalPi.
Does Prescient Design have an API?
No public API is recorded for Prescient Design.
What industry is Prescient Design in?
Prescient Design's product category is AI-Driven Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.